Barreling toward the loss of exclusivity on its blockbuster oncology therapy Keytruda, Merck & Co. has reportedly offered $3 ...

Merck & Co. Inc. closed 42.70% short of its 52-week high of $134.63, which the company reached on June 25th.

Shares of small-biotech MoonLake Immunotherapeutics MLTX rose 18% yesterday following a report issued by the Financial Times ...

However, beneath this success lies a growing concern: the sustainability of this growth trajectory, particularly as ...

Merck, as it prepares a new version of its cancer blockbuster Keytruda, gets a boost in its patent dispute with Halozyme ...

Merck reportedly offered over $3 billion for MoonLake Immunotherapeutics, targeting its late-stage inflammatory drug as it ...

Merck & Co., Inc. (NYSE: MRK) has explored a potential acquisition of Swiss biotech firm MoonLake Immunotherapeutics in a ...

Artisan Partners, an investment management company, released its “Artisan Value Fund” first quarter 2025 investor letter. A ...

After Merck paid a hefty sum to co-develop and co-commercialize HER3-DXd, the drug has suffered notable setbacks in ...

A therapy at the center of their $22 billion alliance failed to extend survival in a type of lung tumor, leading the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...